2. Search Result
Search Result
Results for "

PSMA-positive prostate tumors

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

1

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9992
    Pelgifatamab

    BAY-2315497; PSMA-TTC

    		 PSMA Apoptosis Cancer
    Peligifatamab is a PSMA-targeted α-radioimmunoconjugate with an EC50 of 1.2 nM against human targets. Peligifatamab induces DNA damage, DNA double-strand breaks, cell cycle arrest and apoptosis (Apoptosis) in PSMA-positive prostate cancer cells. Peligifatamab reduces cell viability in a manner dependent on cellular PSMA expression levels. Peligifatamab inhibits tumor growth and tumor-induced abnormal bone growth in prostate cancer bone metastasis models. Peligifatamab exhibits antitumor efficacy in subcutaneous prostate cancer models and xenograft models. Peligifatamab can be used for the research of metastatic castration-resistant prostate cancer .
    Pelgifatamab
  • HY-159500
    Zopocianine

    OTL-0078; OTL78

    		 PSMA Cancer
    Zopocianine (OTL-0078; OTL78) is a near-infrared optical probe targeting PSMA. Zopocianine binds to PSMA on the surface of PSMA-expressing cells, enters cells via receptor-mediated endocytosis, and accumulates in acidic endosomes. Zopocianine selectively accumulates in PSMA-positive cancer tissues and enables the detection of small tumors, primary prostate tumors, and locoregional metastases. Zopocianine helps achieve negative tumor surgical margins during fluorescence-guided surgery. Zopocianine is applicable to research related to prostate cancer .
    Zopocianine
  • HY-114256
    EC1169

    		PSMA Cancer
    EC1169 is a cytotoxic maytansinoid conjugate that specifically binds to prostate-specific membrane antigen (PSMA). EC1169 precisely delivers the maytansinoid B hydrazide payload to PSMA-positive cells to exert antitumor activity. EC1169 only inhibits the growth of PSMA-positive cells but has no effect on PSMA-negative cells, and enables complete recovery in mice bearing PSMA-positive tumors. EC1169 exhibits safety with no body weight loss or major organ damage induced. EC1169 is used in studies of prostate cancer and other PSMA-expressing malignancies .
    EC1169
  • HY-163683
    EB-PSMA-617

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    EB-PSMA-617 is a modified form of PSMA-617 that has enhanced pharmacokinetic properties by conjugating it to Evans Blue (EB) to extend its circulation half-life to improve prostate tumor uptake and radiotherapy efficacy. In preclinical studies using PC3-PIP-loaded mice, EB-PSMA-617 demonstrated prolonged blood half-life, increased accumulation in PSMA-positive tumors, and successful tumor elimination with lower radioactivity .
    EB-PSMA-617
  • HY-159500A
    Zopocianine sodium

    OTL-0078 sodium; OTL78 sodium

    		 Biochemical Assay Reagents Cancer
    Zopocianine sodium (OTL-0078 sodium; OTL78 sodium) is a near-infrared optical probe targeting PSMA. Zopocianine sodium binds to PSMA on the surface of PSMA-expressing cells, enters cells via receptor-mediated endocytosis, and accumulates in acidic endosomes. Zopocianine sodium selectively accumulates in PSMA-positive cancer tissues and enables the detection of small tumors, primary prostate tumors, and locoregional metastases. Zopocianine sodium helps achieve negative tumor surgical margins during fluorescence-guided surgery. Zopocianine sodium is applicable to research related to prostate cancer .
    Zopocianine sodium
  • HY-178248
    PSMA-R2

    		PSMA Cancer
    PSMA ligand 2 is a prostate specific membrane antigen (PSMA) ligand with a glutamate-urea-lysine (GUL) moiety. PSMA ligand 2 can be efficiently labeled with radioactive nuclides such as 68Ga and 177Lu and specifically binds to PSMA-positive tumor cells. PSMA ligand 2 can be used for imaging of PSMA-expressing tumors or cells via PET or SPECT imaging. PSMA ligand 2 can be used for the research of prostate cancer .
    PSMA-R2
  • HY-182240
    Cy5-ZW2-617

    		PSMA Cancer
    Cy5-ZW2-617 is a PSMA ligand with a IC50 of 4.39 nM. Cy5-ZW2-617 specifically binds to PSMA and is thereby internalized by PSMA-positive cells. Cy5-ZW2-617 shows uptake in PSMA-positive tumor cells and tumor xenografts in mice. Cy5-ZW2-617 can be used for the research of prostate cancer .
    Cy5-ZW2-617
  • HY-181853
    NOTA-SP2A-PSMAL

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    NOTA-SP₂A-PSMAL is a ligand targeting prostate-specific membrane antigen (PSMA), which competitively binds to PSMA with high binding affinity and an IC50 value of 0.26 nM. 18F-labeled NOTA-SP2A-PSMAL can be used as a PET tracer for positron emission tomography imaging of prostate cancer. NOTA-SP2A-PSMAL can be used for the synthesis and research of radionuclide conjugates (RDCs) .
    NOTA-SP2A-PSMAL

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: